Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session: Breast cancer, early stage

236MO - Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study

Date

14 Sep 2024

Session

Mini oral session: Breast cancer, early stage

Topics

Cancer Registries

Tumour Site

Breast Cancer

Presenters

Manon de Graaf

Citation

Annals of Oncology (2024) 35 (suppl_2): S309-S348. 10.1016/annonc/annonc1577

Authors

M. de Graaf1, R.C.A.M. Gielen1, S. Balduzzi2, S. Siesling3, S. Linn4, M. Kok5

Author affiliations

  • 1 Tumor Biology And Immunology Department, Netherlands Cancer Institute, 1006 BE - Amsterdam/NL
  • 2 Biometrics Department, Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 3 Department Of Research And Development, IKNL - Netherlands Comprehensive Cancer Organisation, 3501 DB - Utrecht/NL
  • 4 Medical Oncology Department, Netherlands Cancer Institute, 1066 CX - Amsterdam/NL
  • 5 Medical Oncology Department, Netherlands Cancer Institute, 1006 BE - Amsterdam/NL

Resources

This content is available to ESMO members and event participants.

Abstract 236MO

Background

Pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a strong prognosticator for survival in early triple negative breast cancer (TNBC). Chemotherapy is recommended for most patients with stage I TNBC with an increase in use in the neoadjuvant setting as recommended by the recent ESMO guidelines. However, the pCR rate after NACT and the prognostic value in stage 1 TNBC is largely unknown.

Methods

cT1N0M0 TNBC patients who received standard of care NACT followed by surgery between 2012 and 2022 were identified from the Netherlands Cancer Registry. Factors associated with pCR (ypT0/is, ypN0) and the association of pCR with overall survival (OS) were evaluated.

Results

We identified 1144 patients treated with anthracycline and taxane-based neoadjuvant chemotherapy, of whom 472 patients (41.3%) received a platinum-based regimen and 282 (24.7%) received adjuvant capecitabine. The median follow-up was 3.8 years. The majority of patients had a cT1c tumor (94.1%) and most tumors were ductal carcinomas (90.5%). A total of 656 patients (57.3%) had a pCR. Younger age (age <50 years versus ≥50 years; OR 1.75, 95% CI 1.36-2.26) and higher tumor grade (OR 2.07, 95% CI 1.55-2.76) were associated with a higher likelihood of pCR, while patients with a lobular carcinoma had a lower likelihood of having a pCR (OR 0.18, 95% CI 0.03-0.69). Platinum-based treatment was not significantly associated with improved pCR rates (57.1% versus 57.6% for patients not treated with platinum; p=0.9). Patients with a pCR had a better OS compared to patients with residual disease (HR 0.29, 95% CI 0.15-0.56), with a 4-year OS of 98% versus 93% for patients with and without a pCR respectively.

Conclusions

Data from this real-world nationwide Dutch registry on neoadjuvant chemotherapy for stage I TNBC demonstrates pCR to be associated with a favorable long-term outcome in stage 1 TNBC, supporting the use of NACT in this setting.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Siesling: Non-Financial Interests, Personal, Advisory Role: Pfizer. S. Linn: Financial Interests, Institutional, Advisory Role, Advisory role + travel/accomodations/expenses: Daiichi Sankyo; Financial Interests, Institutional, Advisory Role: AstraZeneca, IBM; Non-Financial Interests, Institutional, Advisory Role: Cergentis; Financial Interests, Institutional, Research Funding: Genentech/Roche, AstraZeneca, Tesaro, Merck, Immunomedics, Eurocept Pharmaceuticals, Agendia, Novartis. M. Kok: Financial Interests, Institutional, Research Funding: BMS, Roche, AstraZeneca; Financial Interests, Institutional, Advisory Role: AstraZeneca, Daiichi Sankyo, Domain Therapeutics, Alderaan, MSD; Financial Interests, Institutional, Advisory Role, Advisory role + invited speaker: BMS, Roche; Financial Interests, Institutional, Invited Speaker: Gilead. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.